Navigation Links
Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
Date:5/24/2011

PALO ALTO, Calif. and AUCKLAND, New Zealand, May 24, 2011 /PRNewswire/ -- Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc. (NYSE: VAR), and Auckland UniServices Ltd. of Auckland, New Zealand, today announced that they have entered into a licensing agreement granting Centella exclusive rights to CEN-209, a novel investigational drug designed to enhance the effectiveness of radiotherapy and chemotherapy when treating solid tumors that are hypoxic—or oxygen-starved—and therefore resistant to standard forms of radiotherapy and chemotherapy.

CEN-209 is selectively activated in areas of low oxygen often found within solid tumors.  These areas develop within tumors due to their rapid growth, which impairs the blood vessels bringing nutrients and oxygen, resulting in hypoxia.  

"Hypoxic tumors are generally resistant to radiotherapy and to chemotherapy, and there is no effective treatment for such tumors today," says Thorsten Melcher, PhD, President of Centella Therapeutics.  "Hypoxia occurs in most types of solid tumors, but not necessarily in every patient with a given tumor type. For example, in lung cancer patients, roughly 50 percent of tumors have hypoxic regions.(1)  In the future, successful treatment of hypoxic tumors will likely require identifying affected patients and giving them a hypoxia-specific drug, like CEN-209, in addition to standard treatment."(2)

Radiotherapy works by damaging tumor cells' DNA, but only in well-oxygenated areas, whereas CEN-209 is designed to 'switch on' and damage the DNA only of hypoxic cells, leaving other cells alone," Melcher adds.  "Thus, the two treatment approaches have the potential to complement each other, and CEN-209 is specifically designed to be preferentially used in combination with radiotherapy."

Professor William Wilson and Associate Profes
'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... 15, 2014 Tegra Medical is very pleased to announce ... its new Chief Executive Officer.  Mark was promoted from his ... overseen the company,s four facilities in Massachusetts ... King joined Tegra Medical in 2012 with 20+ years of ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... , CAMBRIDGE, Mass., Oct. 14 Northern Light ( ... EBSCO Publishing (EBSCO) ( www.ebscohost.com ) that ... than 4,000 bio-pharmaceutical, health sciences and general business magazines, ... strategic research portals. SinglePoint users who also subscribe ...
... Luminous Medical, Inc. announced today that it has ... for exclusive rights to incorporate its glucose sensor into ... its monitor to enable clinicians to control hyperglycemia in ... was planning to use a sensing technology based on ...
Cached Medicine Technology:Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing 2Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing 3Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor 2
(Date:4/24/2014)... Philadelphia, Pa. (April 24, 2014) - Contact lenses coated with ... contact lens-related infections, reports a study in Optometry ... American Academy of Optometry . The journal is published ... Wolters Kluwer Health . , Studies in animals and ... with the antimicrobial peptide melimine, according to the new research ...
(Date:4/24/2014)... be boring and irrelevant, could offer an alternative to ... Dr Milena Furtado, and her team from the Australian ... heart cell fibroblast is a close relative to a ... , In research published today in Circulation Research ... unique cells due to their genetic program, and will ...
(Date:4/24/2014)... in the world to discover a gene mutation in ... Ameloblastoma is an odontogenic tumour with a high tendency ... in the posterior of the lower jaw. Ameoloblastomas are ... the jaws as well as loss of several teeth. ... surgery and the recurrence of ameloblastoma, but finding such ...
(Date:4/24/2014)... by a scientist at the University of York reveals ... the development of the nervous system may also play ... A research team, led by Dr Will Brackenbury, ... Biology at York, has studied how voltage-gated sodium channels ... are found in the membranes of excitable cells, such ...
(Date:4/23/2014)... Spokane have developed a new way to detect ... the wheel. , Their recently patented technology is ... in drowsy driversand offers an affordable and more ... detection systems. , Van Dongen"Video-based systems that use ... out of its lane are cumbersome and expensive," ...
Breaking Medicine News(10 mins):Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Boring cells could hold the key to heart disease 2Health News:Breast cancer replicates brain development process 2Health News:WSU innovation improves drowsy driver detection 2
... Goodwin HealthDay Reporter , WEDNESDAY, Feb. 9 ... cancer cell genome revealed never-before-seen changes in DNA that ... By mapping the full genetic blueprint of the tumor, ... development of more targeted drugs and a better understanding ...
... Salamon HealthDay Reporter , WEDNESDAY, Feb. 9 ... than doubled the progression-free survival time for patients with ... new studies. In separate phase 3 trials by ... extended the survival of participants with advanced pancreatic neuroendocrine ...
... parks and recreation sites may be healthier, more physically ... to Penn State researchers. Investments in parks and recreational ... say Geof Godbey, professor emeritus of leisure studies, and ... "There is a strong relationship between how much money ...
... Feb. 9 (HealthDay News) -- About one in 10 ... after. Though typically harmless, some may need treatment because ... "There are several different types of birthmarks, so it ... considering any possible treatments," dermatologist Dr. Sheila Fallon Friedlander, ...
... diagnose heart disease, cancers, HIV and other diseases quickly ... The microsponges are an essential component of Rice University,s ... paper in the journal Small . ... Bioengineering and Chemistry, and his colleagues at Rice,s BioScience ...
... plan from an arm of the National Institutes of ... of most single-gene disorders and gaining new insights into ... to more accurate diagnoses, new drug targets and the ... therapeutic options, according to the plan from the National ...
Cached Medicine News:Health News:First Look at Prostate Cancer Genome Yields Insights 2Health News:First Look at Prostate Cancer Genome Yields Insights 3Health News:2 Experimental Drugs Show Promise for Rare Pancreatic Cancer 2Health News:2 Experimental Drugs Show Promise for Rare Pancreatic Cancer 3Health News:Key to better health care may be a walk in the park 2Health News:Not All Birthmarks Harmless, Expert Says 2Health News:Microsponges from seaweed may save lives 2Health News:Microsponges from seaweed may save lives 3Health News:NHGRI charts course for the next phase of genomics research 2Health News:NHGRI charts course for the next phase of genomics research 3Health News:NHGRI charts course for the next phase of genomics research 4
... Carpal Solution offers relief from CTS pain ... different from other over-the-counter CTS treatments. It ... during sleep, the Carpal Solution gently reshapes ... Tunnel and eliminates hand pain, numbness and ...
... of Hemoglobin S in patient samples. Each ... and 20l of anticoagulated whole blood or ... test kit contains two bottles of phosphate ... and two vials of Sodium Hydrosulfite reagent ...
... tube for the collection, transport and retention ... flow cytometry. The preservative contained in Cyto-Chex ... blood cell cluster of differentiation (CD) markers ... collected in Cyto-Chex BCT are stable at ...
Streck-ONYX-Pack is specially designed for use on Coulter® ONYX Series instruments. Each pack contains diluent and lysing agent. The shelf life is one year from date of manufacture....
Medicine Products: